With two FDA Phase 1 clinical trials completed, Verthermia® intends to start clinical trials using HEATT® in early 2023 with additional funding. Research focused on the effectiveness of HEATT® on additional metastatic cancers, including pancreatic cancer, will be central to new therapies. If successful, new clinical treatments may extend life for patients who have exhausted their treatment options.

With additional funding, Verthermia will expand research on HEATT® and its effectiveness with other cancers. Furthermore, Verthermia® will continue to invest in the development of devices for the delivery of HEATT®.

​